Physician profile
Michael Salim
NPI 1790339471
$845.72
in general payments reported to CMS, 2019-2025
15 companies · $780 in 2025
The $780 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.95 · 2020: $13.50 · 2021: $20.40 · 2022: $20.00 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $277.35 | 2025 | Korlym |
| Medtronic, INC. | $126.38 | 2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $56.81 | 2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $52.82 | 2025 | |
| Ascendis Pharma Endocrinology INC | $51.40 | 2025 | Yorvipath |
| Insulet Corporation | $41.37 | 2025 | Omnipod, Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.40 | 2021-2022 | |
| Amgen INC. | $39.91 | 2025 | Tepezza, Evenity, Prolia |
| Lilly USA, LLC | $39.27 | 2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $32.76 | 2025 | Veozah |
| Tandem Diabetes Care, INC. | $24.64 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $22.41 | 2025 | Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $14.75 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $13.50 | 2020 | |
| Genentech USA, INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Salim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.